1.Three new gallic acid sugaresters from Elaeagnus oxycarpa Schlechtend leaves and their antioxidant and tyrosinase inhibitory activities
Feng-zhen CUI ; Jian-hong FU ; Guo-yan XU ; AYEKABAYR·EKBAYR ; Chang-da MA
Acta Pharmaceutica Sinica 2025;60(2):434-441
Five compounds were isolated and purified from the water extract of
2.Disadvantage of fire twinkling in cupping therapy: "flame-circling in the cup".
Jingxing LI ; Zhen ZHOU ; Jiachun XU ; Zhaohua JIAO ; Yijun FENG ; Yan LI
Chinese Acupuncture & Moxibustion 2025;45(10):1468-1469
Fire twinkling is the common method in cupping therapy. In the teaching materials of acupuncture and moxibustion, and the national standard, Standardized Manipulations of Acupuncture and Moxibustion-Part 5: Cupping Therapy, this cupping technique is operated by igniting an alcohol-soaked cotton ball held with a forceps, placing it inside the cup, taking it out after "turning around in several circles", and placing the cup on the selected area. Based on the clinical experience of chief physician LI Yan, a high-efficient and safe fire twinkling was developed. Clamping the middle part of the cotton ball with a holder, dipping it in 95% ethanol, and squeezing the cotton ball to ensure no ethanol drops left; holding the cup with the dominant hand and covering the ignited cotton ball vertically, removing the cup immediately when the ball touching the cup bottom. Such manipulation mode, "flame going in and out directly", can avoid the potential safety hazards such as residual ethanol left on the cup opening, overheating of cup opening and accidentally falling-off of the ignited cotton ball.
Humans
;
Cupping Therapy/instrumentation*
;
Acupuncture Therapy/instrumentation*
;
Fires
3.The addition of 5-aminolevulinic acid to HBSS protects testis grafts during hypothermic transportation: a novel preservation strategy.
Meng-Hui MA ; Pei-Gen CHEN ; Jun-Xian HE ; Hai-Cheng CHEN ; Zhen-Han XU ; Lin-Yan LV ; Yan-Qing LI ; Xiao-Yan LIANG ; Gui-Hua LIU
Asian Journal of Andrology 2025;27(4):454-463
The aim of this investigation was to determine the optimal storage medium for testicular hypothermic transportation and identify the ideal concentration for the application of the protective agent 5-aminolevulinic acid (5-ALA). Furthermore, this study aimed to explore the underlying mechanism of the protective effects of 5-ALA. First, we collected and stored mouse testicular fragments in different media, including Hank's balanced salt solution (HBSS; n = 5), Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12; n = 5), and alpha-minimum essential medium (αMEM; n = 5). Storage of testicular tissue in HBSS preserved the integrity of testicular morphology better than that in the DMEM/F12 group ( P < 0.05) and the αMEM group ( P < 0.01). Testicular fragments were subsequently placed in HBSS with various concentrations of 5-ALA (0 [control], 1 mmol l -1 , 2 mmol l -1 , and 5 mmol l -1 ) to determine the most effective concentration of 5-ALA. The 2 mmol l -1 5-ALA group ( n = 3) presented the highest positive rate of spermatogonial stem cells compared with those in the control, 1 mmol l -1 , and 5 mmol l -1 5-ALA groups. Finally, the tissue fragments were preserved in HBSS with control ( n = 3) and 2 mmol l -1 5-ALA ( n = 3) under low-temperature conditions. A comparative analysis was performed against fresh testes ( n = 3) to elucidate the underlying mechanism of 5-ALA. Gene set enrichment analysis (GSEA) for WikiPathways revealed that the p38 mitogen-activated protein kinase (MAPK) signaling pathway was downregulated in the 2 mmol l -1 5-ALA group compared with that in the control group (normalized enrichment score [NES] = -1.57, false discovery rate [FDR] = 0.229, and P = 0.019). In conclusion, these data suggest that using 2 mmol l -1 5-ALA in HBSS effectively protected the viability of spermatogonial stem cells upon hypothermic transportation.
Male
;
Animals
;
Testis/cytology*
;
Aminolevulinic Acid/pharmacology*
;
Mice
;
Organ Preservation/methods*
;
Organ Preservation Solutions/pharmacology*
;
Cryopreservation/methods*
4.Short-Term Efficacy of Low-Dose Venetoclax Combined with CHG Priming Regimen in Patients with AML and High-Risk MDS Ineligible for Intensive Chemotherapy.
Yu-Ze YANG ; Mei ZHOU ; Ya-Ru XU ; Wen-Yan XU ; Jie SUN ; Yuan-Yuan ZHU ; Yuan LI ; Zhen-Xing GUO
Journal of Experimental Hematology 2025;33(3):660-665
OBJECTIVE:
To investigate the short-term efficacy and safety of low-dose venetoclax combined with CHG (cytarabine+homoharringtonine+G-CSF) priming regimen in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy.
METHODS:
The data of 14 patients with AML or high-risk MDS admitted to the department of hematology/oncology of the First Hospital of Tsinghua University and 2 cooperative institutions from July 2022 to August 2023 were retrospectively analyzed. All the patients were treated with low-dose venetoclax combined with CHG priming regimen and the early induction (one course) efficacy and adverse reactions were observed.
RESULTS:
Among the 14 patients, 10 were males and 4 were females, with a median age of 69.5 (46-83) years. After 1 cycle of induction chemotherapy, the complete remission (CR) rate was 64.3% (9/14) and overall response rate (ORR) was 78.6% (11/14). Among the 10 patients with adverse prognosis according to cytogenetics and molecular genetics, the CR rate was 50.0% (5/10), and ORR was 70.0% (7/10). In 7 patients with TP53 mutation, the CR rate was 42.9% (3/7) and ORR was 71.4% (5/7). In the 6 patients with complex karyotype, CR rate was 33.3% (2/6) and ORR was 66.7% (4/6). While the CR rate and ORR of 8 non-complex karyotype patients were both 87.5% (7/8), and the difference in CR rate between patients with complex karyotype and non-complex karyotype was statistically significant ( P < 0.05). The adverse reactions of chemotherapy were tolerable, without early treatment-related deaths.
CONCLUSION
Low-dose venetoclax combined with CHG priming regimen can be used as an effective treatment for AML and high-risk MDS patients who are ineligible for intensive chemotherapy, and it is safe and worthy of clinical application.
Humans
;
Leukemia, Myeloid, Acute/drug therapy*
;
Aged
;
Male
;
Female
;
Sulfonamides/therapeutic use*
;
Middle Aged
;
Myelodysplastic Syndromes/drug therapy*
;
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use*
;
Aged, 80 and over
;
Retrospective Studies
;
Cytarabine/administration & dosage*
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
;
Homoharringtonine/therapeutic use*
5.Clinical Characteristics of Acute Leukemia Patients with PICALM∷MLLT10 Fusion Gene Positivity and Prognostic Analysis of Combined Venetoclax Targeted Therapy.
Cheng-Sen CAI ; Zhen YAO ; Ming-Zhu XU ; Zheng LI ; Yan-Jun WU ; Sheng-Li XUE
Journal of Experimental Hematology 2025;33(3):711-719
OBJECTIVE:
To investigate the clinical characteristics and prognostic of venetoclax (VEN) combined targeted therapy in acute leukemia (AL) patients with PICALM∷MLLT10 fusion gene positivity.
METHODS:
A retrospective analysis was conducted on 16 PICALM∷MLLT10-positive AL patients treated at the First Affiliated Hospital of Soochow University from January 2021 to August 2024. These patients were diagnosed by targeted RNA sequencing (RNA-seq) or reverse transcription multiplex PCR, including newly diagnosed and relapsed/refractory (R/R) cases. The immunophenotypes, genetic features, gene mutations, and the efficacy of VEN combination targeted therapy of patients were evaluated.
RESULTS:
Among the 16 cases, 3 were confirmed by reverse transcription multiplex PCR, and 13 were detected through targeted RNA-seq among 528 AL patients, with a detection rate of 2.46%. The averge age of patients was (28.0±8.58) years. Patients exhibited diverse immunophenotypes, including 7 cases of acute myeloid leukemia, 5 of acute T-lymphoblastic leukemia, 1 of acute B-lymphoblastic leukemia, 1 of acute undifferentiated leukemia, and 2 of mixed-phenotype acute leukemia. Among them, 11 had extramedullary disease (EMD), 14 expressed CD7, and 12 expressed CD33. Major co-occurring mutations included PHF6 (6 cases), NOTCH1 (5 cases), and 7 cases with complex karyotypes. Of the 12 patients who received standard induction therapy, 7 did not achieve remission (PR+NR). All 4 patients treated with VEN combination therapy achieved complete remission (CR). Among the 7 induction failure cases, 4 achieved CR upon re-induction with VEN, while the remaining 3 re-induced with standard therapy, did not achieve CR. Thirteen patients received allogeneic hematopoietic stem cell transplantation, including 6 who received maintenance therapy with hypomethylating agents (HMA) alone or in combination with VEN, and seven were followed up. Survival analysis showed that the overall survival was better in the maintenance therapy group (P =0.044).
CONCLUSION
PICALM∷MLLT10-positive AL involves multiple lineages and demonstrates poor response to conventional chemotherapy. VEN combination therapy shows promising efficacy in both newly diagnosed and R/R patients. Post-transplant maintenance therapy with HMA alone or combined with VEN may extend survival; however, further clinical validation is required.
Humans
;
Sulfonamides/therapeutic use*
;
Retrospective Studies
;
Prognosis
;
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use*
;
Adult
;
Male
;
Female
;
Leukemia, Myeloid, Acute/genetics*
;
Mutation
;
Oncogene Proteins, Fusion/genetics*
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*
6.Effect of Juglone on Proliferation Inhibition and RIPK1/RIPK3/MLKL Expression in Acute Myeloid Leukemia Cells.
Chun-Yi LYU ; Xue-Wei YIN ; Zong-Hong LI ; Chen HAN ; Yan WANG ; Zhen-Zhen WANG ; Lyu-Ye LIU ; Rui-Rong XU
Journal of Experimental Hematology 2025;33(4):980-985
OBJECTIVE:
To study the effects and mechanisms of juglone on the proliferation and apoptosis of acute myeloid leukemia (AML) cells.
METHODS:
Juglone and AML targets were collected from public databases, and the intersecting target clusters were taken for functional enrichment analysis to explore the potential mechanism of juglone in the treatment of AML. Then wet experiments were performed to verify. AML cell lines including KG-1a, MV-411, THP-1 and MOLM-13 were treated with different concentrations of juglone for 24 h. MTT assay was used to detect cell viability and determine the IC50, and the most sensitive cell line was screened for subsequent experiments. Flow cytometry was used to detect the apoptosis of cells treated with different concentrations of juglone. Western blot was performed to check the expression of relevant proteins.
RESULTS:
Eleven targets were obtained as potential targets for juglone in the treatment of AML, and the top ten significantly enriched pathways were intrinsic pathway of apoptosis, programmed cell death, cytochrome c-mediated apoptotic response, apoptosis, apoptotic factor-mediated response, regulated necrosis, cytokine signaling in immune system, signaling by interleukins, oncogene induced senescence, and signal transduction. The cell viability of KG-1a, MV-411, THP-1 and MOLM-13 was decreased with increasing juglone concentration after 24 h of juglone treatment (r =-0.992, -0.886, -0.956, -0.910). Among them, MOLM-13 was the most sensitive to juglone. The results of flow cytometry showed that the apoptosis rate of MOLM-13 tended to significantly increase with the increasing concentration of juglone (r =0.99). At the same time point, p-RIPK1/RIPK1, p-RIPK3/RIPK3, and p-MLKL/MLK were decreased in each juglone concentration group compared with control group.
CONCLUSION
Juglone inhibits the viability of KG-1a, MV-411, THP-1 and MOLM-13 cells, and induces apoptosis of MOLM-13 cells, the mechanism of which may be related to the inhibition of RIPK1/RIPK3/MLKL signaling pathway.
Humans
;
Naphthoquinones/pharmacology*
;
Apoptosis/drug effects*
;
Cell Proliferation/drug effects*
;
Leukemia, Myeloid, Acute/pathology*
;
Cell Line, Tumor
;
Receptor-Interacting Protein Serine-Threonine Kinases/metabolism*
;
Protein Kinases/metabolism*
;
Signal Transduction
;
Cell Survival/drug effects*
7.Significance of Serum β2-Microglobulin for Survival and Relapse of Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Yu-Ze YANG ; Ya-Ru XU ; Mei ZHOU ; Wen-Yan XU ; Li-Qiang ZHOU ; Zhen-Xing GUO
Journal of Experimental Hematology 2025;33(4):1057-1062
OBJECTIVE:
To investigate the significance of serum β2-microglobulin (β2-MG) for survival and relapse of patients with diffuse large B-cell lymphoma (DLBCL) in the rituximab era.
METHODS:
Clinical data of 92 patients with DLBCL admitted from December 2003 to July 2015 were retrospectively analyzed. The optimal cutoff value of β2-MG levels for predicting prognosis of the DLBCL patients was determined using receiver operating characteristic (ROC) curve. KaplanMeier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Cox logistic regression analysis was used to explore potential prognostic factors associated with survival. Binary logistic regression analysis was used to analyze the relationship between various factors and relapse.
RESULTS:
The most discriminative cutoff value for β2-MG level was determined to be 2.25 mg/L by the ROC curve. Subgroup analysis showed that patients in the elevated β2-MG (>2.25 mg/L) group had significantly worse PFS(P =0.006) and a trend toward worse OS compared with those in the low β2-MG (≤2.25 mg/L) group(P =0.053). Univariate analysis showed that elevated β2-MG, age>60 years, Ann Arbor stage III-IV, as well as IPI score ≥3 were associated with worse PFS. Binary logistic regression analysis showed that age>60 years and β2-MG>2.25 mg/L were potential influencing factors for relapse of DLBCL patients.
CONCLUSION
Serum β 2-MG might be an important predictor for the survival and relapse of DLBCL patients in the rituximab era.
Humans
;
Lymphoma, Large B-Cell, Diffuse/drug therapy*
;
beta 2-Microglobulin/blood*
;
Rituximab
;
Retrospective Studies
;
Prognosis
;
Female
;
Male
;
Middle Aged
;
Recurrence
;
ROC Curve
8.Antagonistic effect of Lactobacillus reuteri on testicular reproductive toxicity of neonicotinoid insecticides in mice.
Zhen-Han XU ; Pei-Gen CHEN ; Jin-Tao GUO ; Lin-Yan LÜ ; Hai-Cheng CHEN ; Gui-Hua LIU
National Journal of Andrology 2025;31(2):131-137
OBJECTIVE:
To explore the effect of Lactobacillus reuteri on testicular injury in mice exposed to neonicotinoid insecticides (NNI).
METHODS:
Fifteen C57BL/6 male mice were randomly divided into control group (CTRL group), exposure group (NNI group) and Lactobacillus intervention group (NNI-L group). The mice in CTRL group were given 0.02ml/g of 0.5% carboxymethyl cellulose sodium solution by gavage for 14 days. The mice in NNI group were given 0.02 ml/g of NNI mixture by gavage for 14 days. The mice in NNI-L group were given 0.02 ml/g of NNI mixture by gavage and 5×108cfu/ml of Lactobacillus reuteri powder solution for 14 days. Then, the histomorphology and function of testicle were evaluated by hematoxylin-eosin staining, immunofluorescence staining and RNA sequencing.
RESULTS:
Compared with CTRL group, the thickness of testicular seminiferous epithelium in the NNI group was significantly thinner. And the decline in the number of spermatogenic cells and sperm was observed. And the expression of spermatogonial stem cell marker UCHL1 was down-regulated which was significantly improved in NNI-L group compared with the NNI group. The abnormal expressions of hormone and sperm methylation related genes in testis of NNI group were detected by RNA sequencing, with significant down-regulation being found in NPFF and IGF2. While the expression of HSD3B8 was significantly up-regulated. The abnormal expression of these genes could be significantly improved after oral administration of Lactobacillus reuteri.
CONCLUSION
Testicular spermatogenesis and endocrine function can be damaged by NNI exposure. And oral administration of Lactobacillus reuteri protects testis from the adverse effects of NNI toxicity.
Animals
;
Male
;
Limosilactobacillus reuteri
;
Testis/pathology*
;
Mice
;
Mice, Inbred C57BL
;
Insecticides/toxicity*
;
Neonicotinoids/toxicity*
;
Probiotics
;
Spermatogenesis/drug effects*
9.Effect of 3D laparoscopic radical prostatectomy on urinary control and sexual function of patients with prostate cancer.
Jie XIE ; Zhen-Jia DONG ; Qiang-Dong WANG ; Yao YAN ; Xu XIAO
National Journal of Andrology 2025;31(8):703-708
Objective: To investigate the effects of 3D laparoscopic radical resection prostatectomy(LRP) on urinary control and sexual function of patients with prostatic cancer. Methods: A total of 268 patients who were treated with LRP in the Fifth People's Hospital of Huai'an City from January 2019 to May 2022 were selected and divided into 2 groups according to surgical methods, with 134 cases in each group. The patients in the control group were treated with traditional LRP, and the 3D LRP was used in the observation group. The clinical effects of the two groups were compared. Results: The patients in observation group had less blood loss ([135.62±13.58] mL vs [143.18±14.89] mL) and shorter indwelling catheter time ([8.26±1.47] d vs [9.78±1.73] d) compared with control group, but the operation time ([160.52±10.78] min vs [154.47±10.41] min) was longer than that in the control group (P<0.05). The recovery of sexual function and urinary control in the observation group was better than that in the control group after 3, 6 and 12 months of the surgery(P<0.05). After one month of surgery, the scores of ICIQ-SF and 1h urine pad test were lower than those of the control group. The EPIC-UIN score([72.63±6.85] points vs [67.15±5.09] points)of the observation group was higher than that of the control group (P < 0.05). The patients in the observation group had lower level of residual urine volume([60.26±6.63]mL vs [76.89±7.89]mL), higher maximum urine flow rate([7.52±0.46]mL/s vs [6.17±0.43]mL/s) and detrusor pressure([85.19±7.18]mL vs [76.29±6.85]mL) at maximum urine flow rate compared with the control group (P<0.05). There was no difference in the incidence of complications between the observation group and the control group (5.97% vs8.27%,P>0.05). The recurrence rate of tumor 3 years after operation in the observation group was lower than that in the control group (11.94% vs 29.10%, χ2=12.102, P<0.05). Conclusion: 3D LRP has obvious advantages in surgical clarity and precision, which reduces the risk of postoperative complications and improves urinary control ability and sexual function of patients.
Humans
;
Male
;
Prostatectomy/methods*
;
Laparoscopy/methods*
;
Prostatic Neoplasms/surgery*
;
Urination
;
Middle Aged
;
Aged
10.Nonlinear association between serum albumin levels and all-cause mortality in elderly patients with chronic aortic regurgitation.
Ming-Hui LI ; Qing-Rong LIU ; Zhen-Yan ZHAO ; Hai-Yan XU ; Yong-Jian WU
Journal of Geriatric Cardiology 2025;22(4):423-432
BACKGROUND:
Low serum albumin levels are established predictors of adverse outcomes in various cardiovascular conditions. However, the role of serum albumin in mortality among elderly patients with chronic aortic regurgitation (AR) has not been thoroughly investigated. This study aims to assess the relationship between serum albumin levels and mortality in this specific patient population.
METHODS:
Our analysis included 873 elderly AR patients from the China Valvular Heart Disease study, with baseline serum albumin measured at enrollment. Mortality outcomes were monitored for two years post-enrollment, employing a Cox proportional hazards model with a two-piecewise Cox proportional hazards framework to investigate the nonlinear relationship between serum albumin levels and all-cause mortality.
RESULTS:
During the 2-year follow-up period, we observed 63 all-cause deaths. The association between serum albumin levels and all-cause mortality displayed an approximating L-shaped curve, indicating a mortality threshold at 35 g/L. For serum albumin levels below 35 g/L, each 1 g/L decrease was associated with a 25% higher risk of all-cause mortality (HR = 1.25, 95% CI: 1.07-1.45). In contrast, no significant change in mortality risk was observed when serum albumin levels were greater than or equal to 35 g/L. Moreover, when serum albumin is classified as hypoproteinemia (serum albumin < 35 g/L), the higher risks of all-cause death were observed in hypoproteinemic patients (HR = 2.93, 95% CI: 1.50-5.74). More importantly, the association between serum albumin and death was significantly stronger in overweight/obese patients (≥ 24 kg/m2 vs. < 24 kg/m2, P interaction = 0.006).
CONCLUSIONS
In elderly patients with AR, serum albumin levels showed an approximating L-shaped relationship with all-cause death, with thresholds of 35 g/L. Body mass index was significant effect modifiers of the association. These results suggest that serum albumin, as an inexpensive and readily available biochemical marker, may further improve the stratified risk of mortality in older AR patients.

Result Analysis
Print
Save
E-mail